Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept studyDavid Jones, Gideon M. Hirschfield, Yvonne Döerffel et al.|The Lancet. Gastroenterology & hepatology|2017Cited by 186
Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIESStuart C. Gordon, Marlyn J. Mayo, Palak Trivedi et al.|Gastroenterology|2022Cited by 2
Efficacy, safety, and tolerability of seladelpar in patients with compensated liver cirrhosis due to primary biliary cholangitis (PBC): a pooled analysis of phase 2 and phase 3 studiesStuart C. Gordon, Marlyn J. Mayo, Palak Trivedi et al.|Unknown|2021Cited by 0